37637700P00R00_00P00C00A00S00_00200000100600 00Q00100 00s00a00l00e00s00_00E00N00G


Press release


SHARP GROWTH IN NET SALES AGAIN


Longjumeau, April 20, 2016


PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales for the 1st quarter of 2016.

The PCAS Group's consolidated net sales totaled €45.3 million in the 1st quarter of 2016, up by 12.2 % compared to the same period in the previous financial year (+10.2 % at constant exchange rate).



in millions of euros


2016


2015


%

change

2016

At a constant exchange rate


%

change




45.3



40.4



12.2 %



44.5



10.2 %

30.2

25.7

17.5 %

29.5

14.6 %

15.1

14.6

2.9 %

15.0

2.4 %

Net sales at 31 march

Pharmaceutical Synthesis

Fine Specialty Chemicals


Pharmaceutical Synthesis

Pharmaceutical Synthesis activities in Health generated €30.2 million, up 17.5 % compared to 2015 (+14.6 % at constant exchange rate), particularly sustained by the Exclusive activity.


Fine Specialty Chemicals

Net sales of Fine Specialty Chemicals amounted to €15.1 million, up 2.9 % compared to 2015 (+2.4 % at a constant exchange rate), this activity growing both in Performance Additives and Advanced Specialty Chemicals.


Outlook for the current year

The company thus confirms its sales growth targets for 2016 as a whole, excluding growth through acquisition, both in Pharmaceutical Synthesis and in Fine Specialty Chemicals.


NEXT FINANCIAL DISCLOSURE:


Net sales of 1st half 2016, July 19th, 2016


About PCAS

PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €179.1 million in 2015 and employs nearly 900 people in six countries.

For more information about PCAS: www.pcas.com




PCAS


NewCap



Vincent Touraille / Eric Moissenot Emmanuel Huynh / Louis-Victor Delouvrier

PCAS

NewCap

Financial Communication & investors relations


Tel. : +33 1 69 79 61 32 Tel. : +33 1 44 71 98 53

www.pcas.com

pcas@newcap.eu

PCAS SA issued this content on 20 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 20 April 2016 16:13:11 UTC

Original Document: http://www.pcas.com/content/download/4283/70382/version/1/file/PR_PCAS_2016_Q1_sales_ENG.pdf